Japanese 
English 
TOKYO, Japan, 5th Jan. 2022: — PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced it has entered into a multitarget research collaboration and licensing agreement with Roche and Genentech, a member of the Roche Group. Read Full Press Release
Category: ニュース
エーザイとPRISM BioLab共同創製のCBP/β-catenin阻害剤E7386について、臨床におけるPOC（Proof of Concept：創薬概念の検証）を達成
エーザイ株式会社と株式会社PRISM BioLabは、このたび、両社が共同で創製した中分子化合物であるCREB-binding protein （CBP）/β-catenin阻害剤E7386について、臨床におけるPOC（Proof of Concept：創薬概念の検証）を達成したことをお知らせします。
株式会社PRISM BioLab、エーザイ株式会社より資金調達
PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today announced that it has raised ¥100 million in Series C funding through a third-party allotment to Eisai Co. Ltd. on October 14. PRISM has completed the series C financing of 1.4 billion yen in total and aims to achieve...
当社のペプチド模倣化合物に関する論文がACS Omegaに掲載されました
本稿では、ペプチド模倣化合物と実際のペプチドの構造との類似度を評価する手法を開発し、当社の化合物が優位性を示すことが述べられています。
Visualized and Quantitative Conformational Analysis of Peptidomimetics
ACS omega, 6(40), 26601-26612 (2021)
株式会社PRISM BioLab、13億円のシリーズC資金調達を実施
PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today announced that it has raised a total of ¥1.3 billion in Series C funding on August 27. Read Full Press Release
PRISM BioLab、フランスの製薬大手セルヴィエと業務提携
PRISM BioLab provides PepMetics® (peptide mimetic small molecules) Technology for generating Hit and Lead compounds against Servier’s novel target. Read Full Press Release
独自開発のペプチド模倣技術を用いた低分子ライブラリーを提供
PRISM Biolab provides The PRISM Library, proprietary library of peptide mimetic small molecules for screening against Merck’s novel targets Read Full Press Release
PRISM BioLab、ドイツの製薬大手ベーリンガーインゲルハイムに対し独自開発のペプチド模倣技術を用いた低分子ライブラリーを提供
PRISM Biolab provides The PRISM Library, proprietary library of peptide mimetic small molecules for screening against Boehringer Ingelheim’s novel targets Read Full Press Release
合併に関するお知らせ
PRISM Pharma Co.,Ltd. (“Pharma”) and its wholly owned subsidiary, PRISM BioLab Co.,Ltd.(“BioLab”), have merged as of Octorber 1,2018. BioLab succeeds all Pharma’s rights and obligations. Because those two companies were operated as one by the same management, actual business will not change at all after this merger. PRISM BioLab Co., Ltd. President & CEO Dai...